PeptiDream Inc. (TSE: 4587), the Kawasaki-Based Peptide Discovery Platform Company That Operates the Peptide Discovery Platform System (PDPS) for Constrained Cyclic Peptide Design and Runs an Extensive Partnership Book With Novartis, Merck, Genentech, AbbVie, Bristol Myers Squibb, and Eli Lilly Among Others, Announced the Appointment of Three New Executive Vice Presidents Extending the Leadership Restructure That Has Accompanied the Company's Multi-Year Deal-Book Growth and the Increasing Preclinical-to-Clinical Progression of Its Partnered Peptide Programs; PeptiDream's PDPS Platform Screens Trillion-Scale Diverse Non-Standard Peptide Libraries to Identify Molecules That Bind Target Proteins With High Affinity and Specificity, With Applications Spanning Oncology, Immunology, and Rare Disease Peptide Drug Development
PeptiDream Inc. (TSE: 4587), the Kawasaki-based peptide discovery platform company, announced the appointment of three new Executive Vice Presidents. The leadership restructure accompanies the company's multi-year deal-book growth and the increasing preclinical-to-clinical progression of its partnered peptide programs. Company background: PeptiDream operates the Peptide Discovery Platform System (PDPS), a proprietary technology for designing constrained cyclic peptides. PDPS uses genetic-code reprogramming to generate trillion-scale diverse libraries of non-standard peptides (containing modified amino acids not found in natural proteins), which are then screened to identify molecules that bind target proteins with high affinity and specificity. Applications span oncology (peptide-drug conjugates, radioligand-conjugated peptides), immunology (novel immune-modulating peptides), and rare disease peptide drug development. Partnership book: PeptiDream has active collaborations with Novartis (multiple targets), Merck (peptide-radioligand programs), Genentech/Roche (immuno-oncology), AbbVie (multiple targets), Bristol Myers Squibb, Eli Lilly (including the recent obesity-adjacent partnership), and multiple mid-cap biopharmaceutical companies. The constrained cyclic peptide modality PeptiDream specializes in sits between traditional linear peptides (subject to protease degradation and short half-lives) and small-molecule drugs (limited target diversity), and has grown as a distinct drug modality throughout the 2020s as GLP-1 and other peptide successes have expanded the industry's willingness to invest in peptide chemistry platforms.